Cohance Lifesciences Limited has informed the Exchange regarding a press release dated April 27, 2026, titled "Press Release".
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 18.6 pts more than Nifty Smallcap 250 and 19.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Cohance Lifesciences announced the appointment of Umang Vohra as Executive Chairman (effective May 1, 2026) and Group CEO (effective May 20, 2026). Vohra, former CEO of Cipla Limited with over three decades of pharmaceutical industry experience, succeeds Vivek Sharma who stepped down as Executive Chairman for personal reasons. Sharma will serve as Advisor for 9 months to ensure smooth transition. The company describes this as a deliberate, strategic decision by the Board to bring in a leader suited for the company's transformation and next phase of growth as a technology-driven CDMO platform.
The appointment of a high-profile, experienced pharmaceutical leader from outside the company signals confidence in Cohance's growth trajectory. Shareholders may view this positively given Vohra's track record at Cipla, though the departure of founding/executive leadership warrants monitoring.